ClinicalTrials.gg
RecruitingNCT06917742Updated Jul 16, 2026

A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of CPTX2309 and CPTX2309 in Healthy Volunteers, Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by Capstan Therapeutics. Recruiting at 3 sites in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Capstan Therapeutics (part of AbbVie) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Arthritis, Rheumatoid by AbbVie — 5 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · AbbVie.

Planned enrollment
30th of 38
64 · median 210
Started
2025
with 1 other
Phase 1
6 of 80
2 open now
Registered
77th of 80
by date

Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 30th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 77th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 80 studies in Arthritis, Rheumatoid by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Arthritis, Rheumatoid by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.

Read the detailed description

A first-in-human Phase 1, open label study to evaluate safety and tolerability of a single ascending dose (SAD) and multiple ascending dose (MAD) of CPTX2309 intravenously administered to healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.

03

Conditions studied

  • Healthy Volunteers
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus

Keywords

  • Healthy Volunteers
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • CPTX2309
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examination, and clinical laboratory tests obtained during the screening period.
  • Participant is willing and able to adhere to the study visit schedule and other protocol requirements.

RA Only:

  • Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA
  • Presence of rheumatoid factor or ACPA above the
  • Confirmation of at least moderate active disease at screening with the presence of at least 6 swollen and 6 tender joints at screening using the 68 (tender)/66 (swollen) joint count OR the presence of at least 3 joints with active synovitis via MRI assessment.

SLE Only:

  • Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria for SLE
  • Positive ANA>=1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double standard DNA (dsDNA) or anti-Smith (Sm).

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, or clinical laboratory tests beyond what is consistent with a healthy population in the region in which the study is conducted.
  • Use of any medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first administration of CPTX2309.

RA Only:

- Participants diagnosed with Felty's syndrome

SLE Only:

  • Active neuropsychiatric SLE, as defined by the CNS portion of SLEDAI at Screening, or signs of symptoms of neuropsychiatric SLE within 6 months prior to Screening (lupus headache permissible)
  • Note: Other protocol-defined inclusion/exclusion criteria apply
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Part A: SAD Cohorts

    Escalating single doses of CPTX2309 on a specified day to healthy adult participants.

    Drug: CPTX2309

  • Experimental
    Part B: MAD Cohorts

    Escalating multiple doses of CPTX2309 on specified days to healthy adult participants.

    Drug: CPTX2309

  • Experimental
    Part C: SAD Cohorts

    Escalating single doses of CPTX2309 on a specified day to adult participants with moderate to severe RA or SLE.

    Drug: CPTX2309

  • Experimental
    Part D: MAD Cohorts

    Escalating multiple doses of CPTX2309 on specified days to adult participants with moderate to severe RA or SLE.

    Drug: CPTX2309

Interventions

  • DrugCPTX2309

    Intravenous Infusion

  • DrugCPTX2309

    Intravenous Infusion

06

What researchers measure

Primary outcomes

  1. Number of participants with changes in the safety parameters

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  2. Number of participants with clinical laboratory assessment abnormalities

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  3. Number of participants with changes in the vital signs

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  4. Number of participants with changes in the ECG

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  5. Number of participants who develop anti-drug antibodies (ADAs) and Circulating Immune Complex (CIC) formation

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  6. Part A and B: Number of participants with change from baseline in vaccine antibody titers

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants.

    Time frame: Up to approximately 1 Year

  7. Changes in serum cytokine and chemokine levels that are known to be associated with CAR-T cell therapy related toxicity

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  8. Change from baseline in soluble immunoglobulins (Ig)

    To evaluate the safety and tolerability of CPTX2309 administered to healthy adult participants and participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

  9. Part C and D: Change from baseline in vaccination-induced antibody titers

    To evaluate the safety and tolerability of CPTX2309 administered to participants with moderate to severe RA and SLE.

    Time frame: Up to approximately 1 Year

Secondary outcomes

  1. Pharmacokinetic Parameters

    Levels of CAR+ T cells, levels of CPTX2309 components

    Time frame: Up to approximately 1 Year

  2. Pharmacodynamic Parameters

    Levels of circulating B cells expressed as the number of CD19 positive B cells in one microliter of blood by flow cytometry

    Time frame: Up to approximately 1 Year

  3. Part A and B: Pharmacodynamic Parameters

    Percentages of naïve and memory B cells in blood by flow cytometry

    Time frame: Up to approximately 1 Year

  4. Part A and B: Pharmacodynamic Parameters

    Levels of cytokines and chemokines in nanograms per milliliter of serum by ELISA

    Time frame: Up to approximately 1 Year

  5. Part C and D: Number of Participants who develop ADAs

    To evaluate the PK profile of CPTX2309 in participants with moderate to severe RA or SLE.

    Time frame: Up to approximately 1 Year

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 31 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 8, 2025
StartActual
Apr 9, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06917742
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 9, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion